Comparative Pharmacology
Head-to-head clinical analysis: MICONAZOLE 7 versus MYIDYL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MICONAZOLE 7 versus MYIDYL.
MICONAZOLE 7 vs MYIDYL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Imidazole antifungal agent that inhibits fungal cytochrome P450 14α-demethylase, thereby blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
c-Met/ALK inhibitor; inhibits receptor tyrosine kinases MET and ALK, blocking downstream signaling pathways including PI3K/AKT and RAS/RAF/MEK/ERK, leading to reduced tumor cell proliferation and angiogenesis.
Apply 200 mg (one full applicator) intravaginally once daily at bedtime for 7 days.
50 mg orally twice daily without regard to meals.
None Documented
None Documented
Terminal half-life 24-30 hours; prolonged in hepatic impairment
Terminal elimination half-life is approximately 12 hours (range 10–14 hours) in adults with normal renal function; prolonged in renal impairment (up to 24–30 hours).
Primarily fecal (~50%) and renal (~<1% unchanged)
Primarily renal excretion as unchanged drug (~60%) and metabolites (~30%); biliary/fecal excretion accounts for ~10%.
Category A/B
Category C
Antifungal
Antifungal